(CTNM)

NMS – Real vaqt narxi. Valyuta: USD

13.34

-0.31 (-2.27%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

13.34

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 4:00 PM EDT

Kompaniya haqida

Contineum Therapeutics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, Amerika Qo'shma Shtatlarida nevrologiya, yallig'lanish va immunologiya ko'rsatkichlari uchun turli xil kichik molekulali terapiyalarni ishlab chiqish bilan shug'ullanadi. Kompaniyaning asosiy aktivlari PIPE-791, idiopatik o'pka fibrozini va surunkali og'riqni davolash uchun yangi, miyaga kiruvchi, lizosfosfatid kislotasi 1 retseptorining (LPA1R) kichik molekulali ingibitori hisoblanadi. U shuningdek, depressiya va remitting-relapsing ko'p sklerozni davolash uchun muskarin turi 1 retseptorining yangi, kichik molekulali ingibitori bo'lgan PIPE-307ni ishlab chiqadi. Kompaniya ilgari Pipeline Therapeutics, Inc. nomi bilan tanilgan va 2023-yil noyabr oyida Contineum Therapeutics, Inc. nomini o'zgartirgan. Contineum Therapeutics, Inc. 2009-yilda ro'yxatga olingan va San-Diego, Kaliforniyada joylashgan.

Asosiy rahbarlar

Ism	Lavozim
Dr. Daniel S. Lorrain Ph.D.	Chief Science Officer
Dr. Timothy R. Watkins M.D., M.Sc.	Chief Medical Officer & Head of Development
Mr. Austin Chen Ph.D.	Senior VP & Head of Research
Mr. Carmine N. Stengone MBA, MS	President, CEO & Director
Mr. John S. Healy	General Counsel & Corporate Secretary
Mr. Peter T. Slover CPA	Chief Financial Officer
Mr. Steve E. Kunszabo	Senior Director of Investor Relations & Corporate Communications